Collegium Pharmaceutical (COLL) Cash from Financing Activities (2014 - 2026)

Collegium Pharmaceutical has reported Cash from Financing Activities for 13 years, with the latest figure at $292.1 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 703.86% year-over-year to $292.1 million in Q2 2026; TTM through Jun 2026 was $234.1 million, a 585.63% increase from a year earlier, with the FY2025 full-year figure at -$110.2 million, down 81.91% from the prior year.
• Cash from Financing Activities was $292.1 million for Q2 2026 at Collegium Pharmaceutical, up from -$21.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $517.8 million in Q1 2022, with the low at -$114.2 million in Q2 2024.
• Average Cash from Financing Activities over 5 years is $22.0 million, with a median of -$25.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 4614.86% in 2022, then sank 205.3% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$25.8 million in 2022, then plunged by 162.66% to -$67.8 million in 2023, then jumped by 39.14% to -$41.3 million in 2024, then jumped by 47.14% to -$21.8 million in 2025, then soared by 1438.57% to $292.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $292.1 million (Q2 2026), -$21.3 million (Q1 2026), and -$21.8 million (Q4 2025), per Business Quant data.